Allogeneic, or off-the-shelf, cell therapies derived from induced pluripotent stem cells (iPSCs) can be produced in a consistent, scalable manner and can significantly expand the availability and promise of this potentially curative modality. Although only autologous versions are currently approved, cell therapies are becoming an important alternative for treating many relapsed/refractory cancers and show substantial…